Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05893537 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
A Phase 2 study, sponsored by Cognition Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT05893537 is a Phase 2 study that was terminated before completion, run by Cognition Therapeutics. The registered enrollment target is 100 participants.
The verdict
NCT05893537, a Phase 2 study, was terminated before completion, sponsored by Cognition Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
Interventions
- DRUG Placebo Comparator
- DRUG Active Comparator CT1812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-06-16 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05893537
The ClinicalTrials.gov registry entry for NCT05893537 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cognition Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT05893537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05893537 about?
NCT05893537 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).". This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
What is the current status of trial NCT05893537?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-06-16. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT05893537?
The interventions under investigation include: Placebo Comparator (DRUG), Active Comparator CT1812 (DRUG).
Who is sponsoring clinical trial NCT05893537?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.